Business
The business of the industry: deals, pricing, vendors and CROs, recruitment.
Stories
-
Fresenius gets exclusive access to up to 37 WuXi Biologics biosimilar candidates
Fresenius said it has exclusive access to up to 37 identified biosimilar candidates from WuXi Biologics over the next decade, and will pay a fee for service for each candidate it selects. Fresenius holds the commercialization rights, and WuXi Biologics' network is expected to run development.